The War on Generics - Part II
This article was originally published in RPM Report
Executive Summary
Teva says it isn't worried about the more aggressive pricing strategies used by brand companies to blunt blockbuster generic launches. What if the world's largest generic company is wrong? Part II of this two-part series looks at the future of the generic drug industry.
You may also be interested in...
The Lipitor Wars: Who Gets a Piece of a $7 Billion Drug?
The world’s best-selling prescription drug is about to lose patent protection, presenting generic drug companies with their biggest marketing opportunity ever. But potential fraud by first-filer Ranbaxy is complicating the generic landscape for Pfizer’s Lipitor. The stakes are high: How FDA resolves the Ranbaxy debacle will not only determine the winners of the Lipitor battle, but could drive big changes to the generic drug law.
FTC Study of Authorized Generics Gets Off the Ground: Now What?
A Federal Trade Commission analysis of the competitive impact of authorized generics has been in limbo for months. The agency recently received approval to go ahead with the controversial study from the executive branch. What should drug companies expect to receive in the mail?
Betting Generic: Part D, Patents and Proteins Drive Investment Surge
Generic drug companies have been spurned by Wall Street in the past in favor of their brand manufacturing counterparts. With high generic use rates in Medicare Part D and a perceived inevitability of follow-on biologics, investment in pharmaceutical copycats is on the upswing.